M&A Deal Summary

EKF Diagnostics Holdings Acquires Selah Genomics

On March 20, 2014, EKF Diagnostics Holdings acquired healthcare services company Selah Genomics from NMT Capital and The BroadOak Fund for 70M USD

Acquisition Highlights
  • This is EKF Diagnostics Holdings’ 2nd transaction in the Healthcare Services sector.
  • This is EKF Diagnostics Holdings’ largest (disclosed) transaction.
  • This is EKF Diagnostics Holdings’ 1st transaction in the United States.
  • This is EKF Diagnostics Holdings’ 1st transaction in South Carolina.

M&A Deal Summary
Date 2014-03-20
Target Selah Genomics
Sector Healthcare Services
Buyer(s) EKF Diagnostics Holdings
Sellers(s) NMT Capital
The BroadOak Fund
Deal Type Add-on Acquisition
Deal Value 70M USD

Target

Selah Genomics

Greenville, South Carolina, United States
Selah Genomics is a clinical diagnostic company that is rapidly growing at the cutting edge of molecular analysis and next generation sequencing (NGS), and is emerging as a leader in the development of personalized medicine.

Search 199,713 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

EKF Diagnostics Holdings

Cardiff, United Kingdom
Category Company
Founded 1990
Sector Medical Products
Employees386
Revenue 53M GBP (2023)
DESCRIPTION

EKF Diagnostics Holdings is a global, integrated medical diagnostics business. EKF designs and manufactures diagnostic equipment for use within point-of-care settings. EKF Diagnostics is also a manufacturer of liquid reagents used in central laboratory analysers and also sells a number of benchtop analyzers. EKF Diagnostics Holdings was incorporated in 1990 and is based in Cardiff, the United Kingdom.

DEAL STATS #
Overall 2 of 3
Sector (Healthcare Services) 2 of 2
Type (Add-on Acquisition) 2 of 3
State (South Carolina) 1 of 1
Country (United States) 1 of 2
Year (2014) 2 of 2
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-03-20 DiaSpect Medical AB

Uppsala, Sweden

DiaSpect Medical AB point of Care hemoglobin measurements to primary care anywhere in the world.

Buy £21M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-11-12 Advanced Diagnostic Laboratory

San Antonio, Texas, United States

Advanced Diagnostic Laboratory is a PCR-focused testing laboratory certified under the Clinical Laboratory Improvement Amendments (“CLIA”) for high-complexity molecular diagnostics testing. Advanced Diagnostic Laboratory is based in San Antonio, Texas.

Buy -

Seller(S) 2

SELLER

NMT Capital

Norwell, Massachusetts, United States
Category Private Equity Firm
Size Small
Type Sector Agnostic
DESCRIPTION

NMT Capital is a private equity firm focused on tech-oriented growth industries. Areas of interest include medical devices, diagnostics, biotechnology, specialty pharmaceutical, drug discovery tools, software, communications, information technology, and advanced materials. NMT Capital is based in Quincy, Massachusetts.

DEAL STATS #
Overall 5 of 8
Sector (Healthcare Services) 2 of 2
Type (Add-on Acquisition) 4 of 7
State (South Carolina) 2 of 2
Country (United States) 4 of 7
Year (2014) 1 of 1
Size (of disclosed) 4 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2012-10-18 Presidio Pharmaceuticals

San Francisco, California, United States

Presidio Pharmaceuticals is a specialty pharmaceutical company focusing on in-licensing, developing, and commercializing novel and validated therapeutics for chronic viral infections, including HIV-1, HCV, and CMV. Presidio Pharmaceuticals was founded in 2006 and is based in San Francisco, California.

Sell $101M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-01-09 Spectra Analysis Instruments

Marlborough, Massachusetts, United States

Spectra Analysis Instruments is the developer and manufacturer of next-generation Molecular Analysis Instrumentation which solves the critical limitations of current Infrared technology being experienced by the life sciences and other industries, in the essential analysis of complex materials.

Sell -
SELLER

The BroadOak Fund

Investor Investor Investor Investor Investor

Category Growth Capital Firm
Size Small
Type Sector Focused
DESCRIPTION

The BroadOak Fund is the investment affiliate of life science focused investment bank BroadOak Capital Partners. The BroadOak Fund provides growth capital to life sciences tools and service providers that have achieved a level of commercial success. The BroadOak Fund is based in Bethesda, Maryland.

DEAL STATS #
Overall 3 of 6
Sector (Healthcare Services) 1 of 1
Type (Add-on Acquisition) 3 of 5
State (South Carolina) 1 of 1
Country (United States) 3 of 6
Year (2014) 2 of 2
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-02-28 Aragen Bioscience

Morgan Hill, California, United States

Aragen Bioscience, Inc. is a preclinical custom contract research organization that provides in vitro and in vivo research to pharmaceutical, biotechnology and research institutions.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-05-12 Diagnostic BioSystems

Pleasanton, California, United States

Diagnostic BioSystems is committed to enhancing immunohistochemistry results by providing innovative anatomic pathology reagents and systems to improve the practice of pathology. Since the inception, Its prime focus has been to provide high quality products and exceptional customer service and support. Diagnostic BioSystems was founded in 1994 and is based in Pleasanton, California.

Buy -
Mergr

Product

Company

Legal